- Home
- YALA vs SPRY Comparison
YALA vs SPRY Comparison
Compare YALA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | SPRY |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YALA | SPRY |
|---|---|---|
| Price | $7.12 | $9.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 292.4K | ★ 1.3M |
| Earning Date | 03-09-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.79 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $348,904,940.00 | $142,772,000.00 |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $11.99 | $119.97 |
| P/E Ratio | $8.69 | ★ N/A |
| Revenue Growth | 5.80 | ★ 5459.66 |
| 52 Week Low | $3.83 | $6.66 |
| 52 Week High | $9.29 | $18.90 |
Technical Indicators
Market Signals| Indicator | YALA | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 42.92 |
| Support Level | $7.03 | $8.61 |
| Resistance Level | $7.30 | $10.11 |
| Average True Range (ATR) | 0.17 | 0.58 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 65.66 | 38.03 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.